Overview
Lymphoma is one of the most complex and heterogeneous cancers in hematology — encompassing over 80 distinct subtypes with vastly different biology, prognosis, and treatment requirements. Accurate molecular subtyping and individualized, precision treatment are the foundations of optimal lymphoma care. Shanghai is home to China's leading lymphoma precision medicine program, led by a specialist whose international contributions to the field have been recognized with one of France's most prestigious medical science awards.
China Medical Concierge Shanghai (CMCS) connects international patients with Shanghai's top lymphoma specialists, providing end-to-end support from remote consultation through to post-treatment follow-up.
Understanding Lymphoma
What Is Lymphoma?
Lymphoma is a cancer of the lymphatic system — the network of tissues and organs that help rid the body of toxins and waste. Lymphomas arise from lymphocytes (white blood cells) and are broadly divided into two main categories:
- Hodgkin lymphoma (HL) — characterized by the presence of Reed-Sternberg cells; generally highly treatable with chemotherapy and radiation
- Non-Hodgkin lymphoma (NHL) — a diverse group of over 60 subtypes, ranging from indolent (slow-growing) to highly aggressive; treatment varies dramatically by subtype
The most common aggressive NHL subtypes include diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma, T-cell lymphomas, and primary CNS lymphoma. Accurate subtype identification — through immunohistochemistry, flow cytometry, cytogenetics, and molecular profiling — is essential for treatment selection.
Common Symptoms
- Painless swelling of lymph nodes (neck, armpits, groin)
- Fever, night sweats, and unexplained weight loss ("B symptoms")
- Fatigue and weakness
- Itching (pruritus)
- Shortness of breath or chest pain (mediastinal involvement)
- Abdominal pain or swelling (abdominal lymphoma)
Risk Factors
- Immune system deficiency (HIV, immunosuppressive therapy)
- Prior autoimmune disease
- Certain viral infections (EBV, HTLV-1, H. pylori for gastric MALT)
- Family history of lymphoma
- Prior chemotherapy or radiation therapy
Diagnosis & Molecular Subtyping
Accurate diagnosis and molecular subtyping are the foundation of precision lymphoma treatment. The standard workup includes:
- Lymph node biopsy with histopathology — definitive diagnosis and subtype classification
- Immunohistochemistry (IHC) — protein expression profiling for subtype determination
- Flow cytometry — immunophenotyping of lymphoma cells
- Cytogenetics and FISH — chromosomal abnormalities (e.g., MYC, BCL2, BCL6 rearrangements in DLBCL)
- Next-generation sequencing (NGS) — comprehensive molecular profiling for targetable mutations and prognostic markers
- PET-CT — staging and treatment response assessment (the gold standard for FDG-avid lymphomas)
- Bone marrow biopsy — marrow involvement assessment
- Molecular subtyping — e.g., GCB vs. ABC/non-GCB DLBCL; double-hit/triple-hit lymphoma identification
Treatment: Precision Lymphoma Care
Chemoimmunotherapy
The backbone of most B-cell lymphoma treatment is chemoimmunotherapy — combining cytotoxic chemotherapy with anti-CD20 monoclonal antibodies (rituximab, obinutuzumab). Standard regimens include R-CHOP for DLBCL and follicular lymphoma, and R-DHAP or R-ICE for relapsed/refractory disease.
Targeted Therapy
Molecular subtyping enables the use of targeted agents matched to specific lymphoma biology:
- BTK inhibitors (ibrutinib, zanubrutinib, acalabrutinib) — for mantle cell lymphoma, CLL, Waldenström macroglobulinemia, and ABC-DLBCL
- BCL2 inhibitors (venetoclax) — for CLL and selected NHL subtypes
- PI3K inhibitors — for relapsed/refractory follicular lymphoma
- EZH2 inhibitors (tazemetostat) — for EZH2-mutant follicular lymphoma
- Lenalidomide — for mantle cell lymphoma and DLBCL
Immunotherapy
- PD-1/PD-L1 inhibitors — pembrolizumab and nivolumab for Hodgkin lymphoma and selected NHL subtypes
- Bispecific antibodies — mosunetuzumab, glofitamab, epcoritamab for relapsed/refractory B-cell lymphoma
- Antibody-drug conjugates (ADCs) — polatuzumab vedotin, loncastuximab tesirine
CAR-T Cell Therapy
CAR-T (chimeric antigen receptor T-cell) therapy has transformed the treatment of relapsed/refractory large B-cell lymphoma. Approved CAR-T products (axicabtagene ciloleucel, tisagenlecleucel, lisocabtagene maraleucel) achieve complete response rates of 40–54% in patients who have failed two or more prior lines of therapy — a population with historically very poor outcomes. Shanghai is one of China's leading centers for CAR-T therapy in lymphoma.
Autologous Stem Cell Transplantation (ASCT)
For eligible patients with relapsed/refractory lymphoma who achieve a response to salvage chemotherapy, high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) offers the best chance of long-term disease control.
Why Choose Shanghai for Lymphoma Treatment?
- International award-winning precision medicine — Shanghai's lymphoma research has been recognized with France's prestigious Charpak-Dubousset Award
- Molecular subtyping expertise — comprehensive NGS-based profiling to identify every targetable mutation and prognostic marker
- Access to novel agents — bispecific antibodies, ADCs, BTK inhibitors, and CAR-T therapy
- Clinical trial access — participation in international lymphoma trials
- Cost-effective world-class care — significantly lower cost than equivalent treatment in the US, UK, or Singapore
Featured Specialist: Prof. Zhao Weili — Ruijin Hospital, Shanghai Jiao Tong University
Prof. Zhao Weili (赵维莘) is one of China's foremost lymphoma specialists and a globally recognized leader in lymphoma precision medicine, based at Ruijin Hospital, Shanghai Jiao Tong University School of Medicine — one of China's most prestigious academic medical centers and a national leader in hematology.
International Recognition: Charpak-Dubousset Award
In 2024, Prof. Zhao was awarded the Charpak-Dubousset Prize of the French National Academy of Medicine — one of France's most prestigious medical science honors — in recognition of her outstanding international contributions to lymphoma research. This award places her among the most internationally recognized Chinese hematologists of her generation.
National Leadership
Prof. Zhao serves as Vice President of Ruijin Hospital and Director of the Shanghai Institute of Hematology — China's premier hematology research institution, founded by the legendary hematologist Prof. Wang Zhenyi. She is also a recipient of the National Science Fund for Distinguished Young Scholars — China's most competitive individual research grant.
Lymphoma Molecular Subtyping & Precision Treatment
Prof. Zhao's defining clinical and research contribution is the development of a precision diagnosis and treatment system for lymphoma based on comprehensive molecular subtyping. By characterizing the molecular landscape of each patient's lymphoma — including gene expression profiling, mutational analysis, and chromosomal abnormalities — her team can identify the optimal treatment strategy for each individual, improving survival rates beyond what standard treatment protocols achieve.
Clinical Expertise
- Diffuse large B-cell lymphoma (DLBCL) — molecular subtyping-guided precision treatment
- T-cell lymphomas — a particularly challenging subgroup where molecular profiling is critical
- Relapsed/refractory lymphoma — salvage therapy, CAR-T, and transplantation
- Translational research — novel biomarkers and therapeutic targets in lymphoma
For international patients, Prof. Zhao's team offers remote pre-consultation review of biopsy pathology, IHC, molecular profiling, and PET-CT results, enabling a precise subtype assessment and individualized treatment plan to be developed before arrival in Shanghai.
How CMCS Supports Your Journey
CMCS is not a hospital — we are your dedicated medical concierge, providing a trusted bridge between international patients and Shanghai's finest cancer specialists.
Our services include:
- ✅ Direct appointment coordination with Prof. Zhao Weili and the Ruijin Hospital lymphoma team
- ✅ Biopsy pathology, IHC, molecular profiling, and PET-CT translation and pre-consultation review
- ✅ Second opinion facilitation — especially for complex or relapsed/refractory lymphoma
- ✅ Clinical trial eligibility assessment
- ✅ Hospital admission and treatment scheduling support
- ✅ Accommodation and logistics coordination in Shanghai
- ✅ Post-treatment follow-up and remote check-in support
Contact CMCS
If you or a loved one has been diagnosed with lymphoma and would like to explore treatment options in Shanghai, our team is ready to help.
📧 Email: contract@medicalsh.com
💬 WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
🌐 Website: www.medicalsh.com
CMCS — China Medical Concierge Shanghai. Connecting international patients with Shanghai's finest specialists.
0件のコメント